ANCN:NSD-Anchiano Therapeutics Ltd (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 27.26

Change

0.00 (0.00)%

Market Cap

USD 0.03B

Volume

0.16M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapeutics. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/ß-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/ß-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/ß-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.

Company Website : http://www.anchiano.com

Address : One Kendall Square, Cambridge, MA, United States, 02139

Employees : 3

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 0.96

52 Week High : 94.40

Short Ratio : 0.02

52 Week Low : 12.00

Shorted Shares : 65,165

200 Day Moving Average : 34.74

Shorted Shares Previous Month : 190,175

50 Day Moving Average : 61.36

Shares Held By Insiders : 38.17%

Short Percentage : 1.00%

Shares Held by Institutions : 3.46%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

N/A

 USD68.41B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

N/A

 USD56.78B 21.32 15.54
REGN Regeneron Pharmaceuticals, Inc

N/A

 USD53.84B 16.47 12.24
BNTX BioNTech SE

N/A

 USD36.60B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

N/A

 USD36.16B 60.18 35.79
BGNE BeiGene, Ltd

N/A

 USD28.44B N/A N/A
SGEN Seagen Inc

N/A

 USD26.38B 43.18 34.88
RPRX Royalty Pharma plc

N/A

 USD25.42B 22.60 15.19
GMAB Genmab A/S

N/A

 USD22.94B 26.59 3.31
CVAC CureVac N.V

N/A

 USD20.43B N/A N/A

ETFs Containing ANCN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -93.84% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -93.84% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -87.76% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -87.76% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -10.03% 21% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.03% 21% F 10% F
Risk Return Profile  
Volatility (Standard Deviation) 82.60% 35% F 19% F
Risk Adjusted Return -12.15% 26% F 19% F
Market Capitalization 0.03B 4% F 8% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 24.02 6% F 6% F
Price / Cash Flow Ratio -2.75 21% F 63% D
EV/EBITDA 0.02 94% A 99% A+
Management Effectiveness  
Return on Equity -125.60% 21% F 9% F
Return on Invested Capital -118.61% 14% F 6% F
Return on Assets -52.84% 13% F 5% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.02 100% A+ 98% A+
Short Percent N/A N/A N/A N/A N/A
Beta 0.96 71% C- 63% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.